☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
All Posts by Date
Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)
September 9, 2020
Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M
September 9, 2020
Theranica's Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in Europe
September 9, 2020
Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough
September 9, 2020
Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD
September 9, 2020
Sanofi to Present New Data of its Neurology Portfolio at MSVirtual2020
September 9, 2020
Load more...
Back to Home
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions